NEW YORK (GenomeWeb News) – In June, Veracyte entered into a loan and security agreement with an unnamed financial institution for term loans of up to $10.0 million in aggregate, the company said in its recent Form 10-Q filed with the US Securities and Exchange Commission. In June, Veracyte, which went public in November, drew down $5 million in funds under the agreement. It is required to repay the outstanding principal in 30 equal installments starting 18 months after the date of the borrowing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.